Cyclosporine and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
This trial is active, not recruiting.
|Treatments||cyclosporine, etoposide, mitoxantrone hydrochloride|
|Sponsor||University Medical Centre Groningen|
|Start date||February 1995|
|Trial size||25 participants|
|Trial identifier||NCT00002688, CDR0000064413, DUT-KWF-CKVO-9412, EU-95003|
RATIONALE: Some cancers become resistant to chemotherapy drugs. Combining cyclosporine with chemotherapy may prevent resistance to the drugs and allow the cancer cells to be killed.
PURPOSE: Randomized phase II trial to study the effectiveness of adding cyclosporine to combination chemotherapy in treating patients with relapsed or refractory acute myeloid leukemia.
|United States||No locations recruiting|
|Other countries||No locations recruiting|
|Brussels (Bruxelles), Belgium||Cliniques Universitaires Saint-Luc||no longer recruiting|
|Leuven, Belgium||U.Z. Gasthuisberg||no longer recruiting|
|'s-Gravenhage (Den Haag, The Hague), Netherlands||Leyenburg Ziekenhuis||no longer recruiting|
|Amsterdam, Netherlands||Academisch Medisch Centrum||no longer recruiting|
|Amsterdam, Netherlands||Academisch Ziekenhuis der Vrije Universiteit||no longer recruiting|
|Groningen, Netherlands||Academisch Ziekenhuis Groningen||no longer recruiting|
|Maastricht, Netherlands||Academisch Ziekenhuis Maastricht||no longer recruiting|
|Rotterdam, Netherlands||University Hospital - Rotterdam Dijkzigt||no longer recruiting|
|Utrecht, Netherlands||Academisch Ziekenhuis Utrecht||no longer recruiting|
|Basel, Switzerland||University Hospital||no longer recruiting|
|Bern, Switzerland||Inselspital, Bern||no longer recruiting|
|Zurich, Switzerland||Universitaetsspital||no longer recruiting|
Male or female participants at least 18 years old.
DISEASE CHARACTERISTICS: Acute myelogenous leukemia (AML) in the following categories: Refractory to initial standard therapy consisting of idarubicin/cytarabine and amsacrin/cytarabine (on protocol HOVON 29) First or subsequent relapse following complete response to standard chemotherapy (on protocols HOVON 4/4A or 11 or any other protocol) At least 6 months between mitoxantrone/etoposide and relapse No myelodysplasia PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Not specified Hematopoietic: Not applicable Hepatic: Bilirubin no greater than 2 x normal Alkaline phosphatase no greater than 2 x normal Renal: Creatinine no greater than 1.7 mg/dl (150 micromoles/liter) OR Creatinine clearance at least 60 ml/min Cardiovascular: No uncontrolled hypertension No other severe cardiac disease Pulmonary: No severe pulmonary disease Other: No known intolerance to any study drug No uncontrolled severe infection Not HIV seropositive No severe neurologic or metabolic disease No concomitant malignancy except: Nonmelanomatous skin cancer In situ cervical carcinoma No pregnant women PRIOR CONCURRENT THERAPY: See Disease Characteristics
|Official title||AML-MVPCYA: ADDITION OF CYCLOSPORIN A TO THE COMBINATION OF MITOXANTRONE AND ETOPOSIDE (VP 16,213) TO OVERCOME RESISTANCE TO CHEMOTHERAPY IN REFRACTORY AML: A RANDOMIZED PHASE II STUDY|
|Description||OBJECTIVES: I. Evaluate whether the addition of cyclosporine (CYSP) to mitoxantrone (DHAD) and etoposide (VP-16) increases the response rate and duration of response in adults with refractory or relapsed acute myelogenous leukemia (AML). II. Correlate response to this treatment with the presence of P-glycoprotein (P-gp) multidrug resistance (MDR) and the degree of in vitro modulation of leukemic blasts, including CD34+ blasts. III. Correlate response with the presence of other resistance mechanisms, such as atypical MDR and non-P-gp phenotype. IV. Evaluate the toxicity of this treatment in AML patients. V. Study the effect of CYSP on DHAD and VP-16 pharmacokinetics and metabolism and, potentially, on intracellular drug accumulation. OUTLINE: Randomized study. The following acronyms are used: CYSP Cyclosporine, NSC-290193 DHAD Mitoxantrone, NSC-301739 VP-16 Etoposide, NSC-141540 Arm I: 2-Drug Combination Chemotherapy. DHAD; VP-16. Arm II: 2-Drug Combination Chemotherapy with Drug Resistance Inhibition. DHAD; VP-16; with CYSP. PROJECTED ACCRUAL: At least 25 patients/arm will be entered over approximately 3 years.|
Call for more information